[Synthesis and hypoglycemic activity of bis(L-malato)oxovanadium(IV)].

In order to create new oral vanadyl organic complexes-based drugs for the treatment of diabetes mellitus biligand vanadyl derivative of L-malic acid (bis(L-malato)oxovanadium(IV) was prepared and its potential as a novel hypoglycemic agent was studied in the streptozotocin-diabetic rats. We show that the oral administration of bis(L-malato)oxovanadium(IV) with drink water significantly reduced glucose concentration in blood and urine, as well as the level of glycated proteins in the streptozotocin-diabetic rats.

[Modern approaches to pharmacotherapy of diabetes mellitus type II].

The pharmacological approaches to the treatment of type 2 diabetes mellitus were reviewed. Special attention was paid to the new therapeutic agents that are able to decrease plasma glucose levels. The possible mechanisms of the hypoglycemic effects are discussed.

[Vanadium compounds--a new class of therapeutic agents for the treatment of diabetes mellitus].

Vanadium compounds as insulin mimics with promising therapeutic properties are reviewed. The biological effects of both inorganic forms of vanadium and vanadyl organic complexes are decried for various animal models. These effects include hypoglycemic and insulin reserve actions, insulin sensitivity enhance, cholesterol lowering and other manifestations.